Dear Editor, Acute kidney injury (AKI) carries high mortality and morbidity [1, 2] . Two studies recently suggested the potential benefit of renin-angiotensin system (RAS) blockers (angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)) after AKI [3, 4] . The first one reported a lower mortality after 1 year of follow-up in patients receiving an ACEi or ARB after an episode of AKI (KDIGO stages 1 to 3) at ICU discharge (20/109 (18%) vs 153/502 (31%), p = 0.001) [3] . The second one was a retrospective cohort study including adults after an episode of AKI during hospital stay (with 18% only of ICU-patients and only 7% of KDIGO stage 3) [4] . It concluded that exposure to an RAS blocker within the first 6 months after hospital discharge was associated with a 15% decrease in all-cause mortality (HR, 0.85; 95%CI, 0.81-0.89).
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We performed an ancillary of the AKIKI trial [5] , which included 619 ICU patients with severe AKI (KDIGO stage 3) in order to evaluate the potential effect of RAS blockers on long-term mortality.
All patients discharged alive from ICU were included, and their long-term prognosis (2-year all-cause mortality) was assessed according to treatment with ACEi/ARB at ICU discharge using both univariate and multivariate analyses.
Among 348 patients discharged alive from ICU, 45 (12.9%) received an ACEi/ARB at ICU discharge (see Table 1 for patient characteristics). Patients without ACEi/ARB were more severe as attested by a higher SAPS 3 (p = 0.02) and a higher rate of catecholamine infusion (p = 0.008) during AKI. However, 2-year all-cause mortality did not significantly differ between the two groups (12/45 (27%) with ACEi/ARB vs 55/303 (18%) without, p = 0.18). Mortality risk was not associated with non-prescription of ACEi/ ARB after adjustment for prognostic variables (p = 0.21) ( Table 2) . We acknowledge that our study did not assess introduction nor interruption of ACEi/ARB after ICU discharge. One consequence of the severity of AKI in our study is that most patients had not fully recovered at ICU discharge. In this condition, physicians in charge could be reluctant to initiate ACEi/ARB in ICU but treated the patients later.
Our study does not confirm findings from two recent studies [3, 4] . This discrepancy could be explained by a different population (less severe AKI in previous studies) and/or a lack of power of our study but in any case warrant the performance of a randomized controlled trial of ACEi/ARB at ICU discharge after an episode of severe AKI.
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